Oliver Willacy

Oliver Willacy

Auto-generated profile, based on publicly available information

Oliver Willacy

Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GMGiuseppe Mazza
Giuseppe Mazza
WAWalid Al-Akkad
Walid Al-Akkad
ATAndrea Telese
Andrea Telese
LLLisa Longato
Lisa Longato
LULuca Urbani
Luca Urbani
MPMassimo Pinzani
Massimo Pinzani
The development of human liver scaffolds retaining their 3-dimensional structure and extra-cellular matrix (ECM) composition is essential for the advancement of liver tissue engineering. We report the design and validation of a new methodology for the rapid and accurate production of human acellular liver tissue cubes (ALTCs) using normal liver tissue unsuitable for transplantation. The application of high shear stress is a key methodological determinant accelerating the process of tissue decellularization while maintaining ECM protein composition, 3D-architecture and physico-chemical properties of the native tissue. ALTCs were engineered with human parenchymal and non-parenchymal liver cell lines (HepG2 and LX2 cells, respectively), human umbilical vein endothelial cells (HUVEC), as well as primary human hepatocytes and hepatic stellate cells. Both parenchymal and non-parenchymal liver cells grown in ALTCs exhibited markedly different gene expression when compared to standard 2D cell cultures. Remarkably, HUVEC cells naturally migrated in the ECM scaffold and spontaneously repopulated the lining of decellularized vessels. The metabolic function and protein synthesis of engineered liver scaffolds with human primary hepatocytes reseeded under dynamic conditions were maintained. These results provide a solid basis for the establishment of effective protocols aimed at recreating human liver tissue in vitro.

8 November 2019 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
AMAlejandro E Mayorca-Guiliani
Alejandro E Mayorca-Guiliani
OWOliver Willacy
Oliver Willacy
CMChris D. Madsen
Chris D. Madsen
MRMaria Rafaeva
Maria Rafaeva
SHStefanie Elisabeth Heumüller
Stefanie Elisabeth Heumüller
RRRaphael Reuten
Raphael Reuten

20 September 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NJNikolai Juul
Nikolai Juul
FAFatemeh Ajalloueian
Fatemeh Ajalloueian
OWOliver Willacy
Oliver Willacy
CCClara Ibel Chamorro
Clara Ibel Chamorro
MFMagdalena Fossum
Magdalena Fossum
Urogenital reconstructive surgery can be impeded by lack of tissue. Further developments within the discipline of tissue engineering may be part of a solution to improve clinical outcomes. In this study, we aimed to design an accessible and easily assembled tubular graft with autologous tissue, which could be constructed and implanted as a single-staged surgical procedure within the premises of an ordinary operating room. The ultimate goals would be to optimize current treatment-options for long-term urinary diversion. Therefore, we evaluated the optimal composition of a collagen-based scaffold with urothelial micrografts in vitro, and followingly implanted the construct in vivo as a bladder conduit. The scaffold was evaluated in relation to cell regeneration, permeability, and biomechanical properties. After establishing an optimized scaffold in vitro, consisting of high-density collagen with submerged autologous micrografts and reinforced with a mesh and stent, the construct was successfully implanted in an in vivo minipig model. The construct assemblance and surgical implantation proved feasible within the timeframe of a routine surgical intervention, and the animal quickly recovered postoperatively. Three weeks post-implantation, the conduit demonstrated good host-integration with a multilayered luminal urothelium. Our findings have encouraged us to support its use in more extensive preclinical large-animal studies.

16 March 2020 in Nature Protocols
Verified
Journal Article
Open access
PDF file
AMAlejandro E. Mayorca-Guiliani
Alejandro E. Mayorca-Guiliani
OWOliver Willacy
Oliver Willacy
CMChris D. Madsen
Chris D. Madsen
MRMaria Rafaeva
Maria Rafaeva
SHStefanie Elisabeth Heumüller
Stefanie Elisabeth Heumüller
RRRaphael Reuten
Raphael Reuten
An amendment to this paper has been published and can be accessed via a link at the top of the paper.